Life Science Start-Ups: Tech Transfer Deals, November 2013
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2013.
You may also be interested in...
Deals Shaping The Medical Industry, March 2020
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.
Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2019
Device financing during 2019’s final quarter totaled $1.6bn, a substantial decrease from Q3’s $4.05bn. Merger and acquisition activity, almost doubled from the previous quarter reaching $6.1bn; Stryker’s 4.7bn takeover of Wright Medical was the only billion-dollar transaction. Financings by diagnostics/research players totaled $1.3bn (the lowest quarter of the year) and eight companies were acquired, five of which together were valued at $981m.
Deals In Depth: January 2020
Nurix and Sanofi signed a $2.55bn deal using DELigase DNA-encoded libraries to targeted protein degradation therapies for the three targets. Lilly enhanced its immunology pipeline with the $1.1bn takeover of Dermina and its atopic dermatitis antibody lebrikizumab. Biopharma financing was slightly up, while device funding somewhat decreased.
Need a specific report? 1000+ reports available
Buy Reports